TP患者应用IL-11联合重组人血小板生成素治疗的临床疗效及安全性

Clinical Efficacy and Safety of IL-11 Combined with Recombinant Human Thrombopoietin in the Treatment of TP Patients

目的:探讨血小板减少症(TP)患者应用白细胞介素(IL)-11联合重组人血小板生成素注射液治疗的临床疗效及安全性。方法:选取2022年8月至2023年8月在漯河医学高等专科学校第二附属医院接受治疗的150例TP患者,随机均分为常规组与联合组,每组各纳入75例。常规组给予应用IL-11治疗,联合组在常规组的基础上联合应用重组人血小板生成素输注治疗。观察两组患者治疗期间血小板计数的变化,比较血小板计数达标时间;治疗14 d,观察血清学检测指标的变化;出院前统计两组患者不良反应发生情况并比较。结果:治疗3 d、7 d、14 d时,联合组患者血小板计数均高于常规组;联合组患者血小板计数恢复至≥50×10^(9)·L^(-1)时间、≥70×10^(9)·L^(-1)时间、≥100×10^(9)·L^(-1)时间均短于常规组;治疗14 d时,联合组血清促血小板生成素(TPO)、IL-6、肿瘤坏死因子-α(TNF-α)水平均低于常规组,差异均具有统计学意义(P<0.05)。两组患者不良反应总发生率的差异无统计学意义(P>0.05)。结论:IL-11联合重组人血小板生素注射液治疗TP可获得理想的临床疗效,能有效缩短血小板达标时间,且联合方案安全性可靠。

Objective Exploring the clinical efficacy and safety of using interleukin-11(IL-11)combined with recombinant human thrombopoietin injection in the treatment of patients with thrombocytopenia(TP).Methods 150 TP patients who received treatment at the Second Affiliated Hospital of Luohe Medical College from August 2022 to August 2023 were randomly divided into a conventional group and a combination group,with 75 patients in each group.The conventional group was treated with IL-11,while the combination group was treated with recombinant human thrombopoietin infusion in addition to the conventional group.Observe the changes in platelet count during treatment in two groups of patients and compare the time when platelet count meets the standard;After 14 days of treatment,observe the changes in serum indicators;Count and compare the incidence of adverse reactions between two groups of patients before discharge.Results At 3,7,and 14 days of treatment,the platelet count of patients in the combination group was higher than that in the conventional group;The time for platelet count recovery to≥50×10^(9)·L^(-1),≥70×10^(9)·L^(-1),and≥100×10^(9)·L^(-1) in the combined group was shorter than that in the conventional group;After 14 days of treatment,serum levels of thrombopoietin(TPO),IL-6 and tumor necrosis factor-α(TNF-α)in the combination group were lower than those in the conventional group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion The combination of IL-11 and recombinant human thrombopoietin injection can achieve ideal clinical efficacy in the treatment of TP,effectively shorten the time for platelet compliance,and the combination regimen is safe and reliable.